<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080153</url>
  </required_header>
  <id_info>
    <org_study_id>151119-OcF</org_study_id>
    <nct_id>NCT05080153</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin Supplementation in Glaucoma Patients</brief_title>
  <official_title>The Effects of Vitamin Supplementation Containing L-Methylfolate (Ocufolin® Forte) on Retinal Venous Pressure and Homocysteine Plasma Levels in Patients With Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Devogelaere Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Devogelaere Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact of targeted vitamin supplementation on retinal venous pressure (RVP) and steady&#xD;
      state pattern ERG (SSpERG) in patients with RVP 15mmHg or more above intra-ocular pressure&#xD;
      (IOP) and serum homocystein 12µmol/l or more, with signs of progression in spite of adequate&#xD;
      IOP control, as evidenced by SSpERG abnormality with or without structural progression or&#xD;
      visual field progression,&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Provided the inclusion criteria were met, RVP measurement was repeated, and a 1 capsule/day&#xD;
      regimen of Ocufolin® forte was subsequently carried out for a duration of 3 months, after&#xD;
      which repeat measurements of IOP, SSpERG, and RVP were performed, along with dilated&#xD;
      fundoscopy. .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RVP effect</measure>
    <time_frame>3 months</time_frame>
    <description>measurement of RVP lowering effect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SSpERG effect</measure>
    <time_frame>3 months</time_frame>
    <description>measurement of improvement of SSpERG</description>
  </primary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Glaucoma</condition>
  <condition>Homocysteinemia</condition>
  <condition>Elevated Retinal Venous Pressure</condition>
  <condition>Abnormal Steady State Pattern Electroretinography</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ocufolin forte</intervention_name>
    <description>start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with glaucoma and/or ocular vascular disease with signs of progression in spite of&#xD;
        well controlled IOP and elevated RVP, with fasting serum Hcy level &gt; 12 µmol/l&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  glaucoma and/or ocular vascular disease in at least on eye&#xD;
&#xD;
          -  abnormal SSpERG&#xD;
&#xD;
          -  RVP measured using an ophthalmodynamometer at least 15 mmHg higher than intra-ocular&#xD;
             pressure (IOP),&#xD;
&#xD;
          -  fasting serum Hcy level &gt; 12 µmol/l&#xD;
&#xD;
          -  stable and well-controlled IOP (with or without IOP-lowering treatment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  starting other systemic or ocular medications with potential impacts on RVP within a&#xD;
             month before entering the study or during the course of the study&#xD;
&#xD;
          -  starting or changing the dosage of other medications with potential impact on SSpERG&#xD;
             within 3 months before entering the study or during the course of the study&#xD;
&#xD;
          -  non-adherence to the follow-up schedule&#xD;
&#xD;
          -  inability to perform a proper RVP measurement using ophthalmodynamometry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thibaut Devogelaere, MD, FEBO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vision Devogelaere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Devogelaere Vision</name>
      <address>
        <city>Oudenburg</city>
        <zip>8460</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Devogelaere Vision</investigator_affiliation>
    <investigator_full_name>Thibaut Devogelaere</investigator_full_name>
    <investigator_title>Dr T Devogelaere, MD, FEBO</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>homocysteine plasma levels</keyword>
  <keyword>L-methylfolate</keyword>
  <keyword>ophthalmodynamometry</keyword>
  <keyword>retinal venous pressure (RVP)</keyword>
  <keyword>steady state pattern electroretinography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

